Peer-Reviewed Validation Case Study: CytoSolve® Systems Architecture for Acute Myeloid Leukemia with Ermaris Bio, Inc.

Partner Description

Ermaris Bio, Inc.
Ermaris Bio, Inc. is a biotechnology company focused on advancing precision oncology through systems biology, computational modeling, and translational cancer research. The company collaborates with academic and clinical partners to uncover mechanistic insights that inform next-generation therapeutic strategies.

Challenge

Acute myeloid leukemia (AML) is a multifactorial hematologic malignancy driven not only by genetic mutations within leukemic cells but also by complex, dynamic interactions with the surrounding tumor microenvironment. These interactions span immune cells, endothelial cells, stromal cells, and metabolic niches, creating a highly coupled network that promotes immune evasion, proliferation, survival, and drug resistance.

Prior to this work, AML research lacked a comprehensive, peer-reviewed systems framework capable of organizing thousands of molecular interactions into a coherent, testable architecture suitable for discovery of therapeutic targets and combination strategies.

How CytoSolve® Helped

CytoSolve, Inc. collaborated with Ermaris Bio scientists to develop and validate a molecular systems architecture of the AML microenvironment using the CytoSolve® platform. CytoSolve enabled a rigorous, PRISMA-guided systematic bioinformatics review of peer-reviewed literature spanning more than four decades.

The platform organized hundreds of validated molecular pathways and signaling interactions into a layered systems architecture capturing intracellular signaling within AML cells and intercellular crosstalk with stromal, endothelial, immune, and metabolic cell populations. This architecture preserved pathway provenance while enabling integrative analysis of angiogenesis, immune suppression, cell survival, and proliferation mechanisms. The resulting framework was designed to directly support downstream in silico modeling, target identification, and combination therapeutic discovery.

Key Benefits Realized

  • Peer-reviewed validation of a comprehensive molecular systems architecture for AML.
  • Integration of genetic, signaling, metabolic, and microenvironmental interactions into a unified framework.
  • Identification of convergent molecular drivers of immune suppression, angiogenesis, and leukemic cell survival.
  • Systems-level mapping of potential single and combination therapeutic targets.
  • Reusable architecture designed for continuous expansion as new AML research emerges.

Outcome

The collaboration resulted in a high-impact, peer-reviewed publication in Cancers (MDPI, 2022), establishing the first validated molecular systems architecture of the AML microenvironment. The study demonstrated how CytoSolve® enables rigorous organization of complex biological knowledge into an actionable systems framework, supporting translational discovery and combination therapy development. For Ermaris Bio, this work provided a scientifically validated foundation to guide precision oncology research and future therapeutic innovation in AML